Nagy V, Csürös L, Iskum M
Second Department of Medicine, Municipal Ujpesti Hospital, Outpatient Clinic, Budapest.
Ther Hung. 1990;38(2):77-80.
The initiation of anticoagulants and drugs with platelet aggregation inhibiting properties is justified for the treatment of myocardial infarction in a great number of conditions. The well-known complications of this therapy are gastro-intestinal haemorrhage and the concomitant discomfort. In the period from 1983 to 1986 Histodil was given as adjuvant to therapy for infarction patients with ulcer, gastro-intestinal haemorrhage, hyperacidity or other epigastric burn-pain syndrome in history. The patients treated at our department between 1979-82 had not received Histodil for this purpose. According to the retrospective examinations the preventive effect of Histodil prophylaxis was 100%. Therefore the drug may be recommended to myocardial infarction patients in whom the inhibition of haemostasis means an increased risk of gastro-intestinal alteration.
在许多情况下，使用抗凝剂和具有血小板聚集抑制特性的药物来治疗心肌梗死是合理的。这种治疗方法众所周知的并发症是胃肠道出血和随之而来的不适。在1983年至1986年期间，Histodil被用作有溃疡、胃肠道出血、胃酸过多或有其他上腹部灼痛综合征病史的梗死患者治疗的辅助药物。1979 - 1982年期间在我们科室接受治疗的患者未为此目的使用Histodil。根据回顾性检查，Histodil预防的效果为100%。因此，对于止血抑制意味着胃肠道改变风险增加的心肌梗死患者，可推荐使用该药物。
